Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03662282
Other study ID # 00033519
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 23, 2018
Est. completion date January 7, 2019

Study information

Verified date July 2019
Source University of South Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis


Description:

An intermediate population, Investigational New Drug study, to provide an alternate intravenous fat nutrition, Omegaven®, to help improve liver function while providing adequate nutrition for critically ill infants with parenteral nutrition associated cholestasis


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date January 7, 2019
Est. primary completion date January 7, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Greater than 14 days old

- Has parenteral nutrition associated cholestasis defined as at least 2 consecutive direct bilirubin >2 mg/dL with anatomical or functional short gut (OR >4 mg/dL if intact intestine) obtained at least 1 week apart with a ratio of direct: total bilirubin > 0.4

- Patient is parenteral nutrition dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require parenteral nutrition for at least 3 more weeks

- Patient has not responded to other therapeutic approaches for parenteral nutrition-associated liver disease such as : cycling of parenteral nutrition, avoiding overfeeding, reduction/removal of copper and manganese from parenteral nutrition, advancement of enteral feeding, and use of Ursodiol

- Patient has been on at least 2 weeks of SMOFLIPIDs with no improvement or worsening of direct bilirubin levels

- Signed patient informed consent

- The patient is expected to have a reasonable possibility of survival

- No other known etiology of cholestasis other than parenteral nutrition-associated liver disease at the time of Omegaven® initiation

Exclusion Criteria:

- Known causes of cholestasis other than parenteral nutrition-associated liver disease including but not limited to Hepatitis C, Cystic fibrosis, biliary atresia, and alpha 1 antitrypsin deficiency are present, prior to Omegaven® initiation

- Known fish or egg allergy

- Any of the contraindications to use of Omegaven®:

1. Active new infection at the time of initiation of Omegaven®

2. Hemodynamic instability

3. Recent use of medications with associated risk of bleeding, including NSAIDs

4. Active coagulopathy or bleeding

5. Platelet counts persistently under 30,000 despite transfusions

6. Unstable hyperglycemia

7. Impaired lipid metabolism (triglycerides >1000 mg/dL) while on 1 g/kg/day or less of Intralipid

8. History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.)

9. Unstable diabetes mellitus

10. Collapse and shock

11. Stroke/ Embolism

12. Cardiac infarction within the last 3 months

13. Undefined coma status

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Omegaven
Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury

Locations

Country Name City State
United States USF Health Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
University of South Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participant With Decrease in Direct Bilirubin Level Number of participant with decrease in direct bilirubin levels within 30 days of treatment First month of treatment
Secondary Number of Participant With Resolution of Direct Hyperbilirubinemia Number of participant with Direct bilirubin level of <2mg/dL at discontinuation of treatment 2 months
Secondary Number of Participant With Preservation of Length Monitoring of weekly length while the patient is receiving Omegaven® treatment Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment
Secondary Number of Participant With Preservation of Head Circumference Monitoring of weekly head circumference while the patient is receiving Omegaven® treatment Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment
Secondary Number of Participant With Preservation of Normal Weight Gain Monitoring of daily weight gain while the patient is on Omegaven® Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment
See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Completed NCT00738101 - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants N/A
Completed NCT00004414 - Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis N/A
Recruiting NCT02334293 - Omegaven® as Parenteral Nutrition N/A
Recruiting NCT01252043 - Retrospective Review of CT and MR in Pediatric Patients With Cholestasis N/A
Completed NCT00846963 - Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Phase 2/Phase 3
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Completed NCT01194063 - Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Phase 3
Recruiting NCT01998620 - Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Phase 4
Completed NCT00080236 - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation Phase 2
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3
Active, not recruiting NCT00004315 - Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Terminated NCT02267707 - Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Phase 1
Completed NCT02357576 - Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD Phase 3
Completed NCT02721277 - SMOFlipid to Lessen the Severity of Neonatal Cholestasis Phase 1/Phase 2
Terminated NCT02767648 - Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region N/A
Completed NCT01073202 - Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation N/A